Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative cannabinoid-based therapies for neuropsychiatric conditions. Founded in 2007, Zynerba has made significant strides in the industry, particularly with its transdermal delivery systems that enhance the bioavailability of cannabinoids. The company’s flagship products, including Zygel, are designed to treat conditions such as autism spectrum disorder and osteoarthritis, setting Zynerba apart with their unique formulation and delivery methods. With a strong commitment to research and development, Zynerba has positioned itself as a leader in the cannabinoid therapeutics market, achieving notable milestones in clinical trials and regulatory advancements. As it continues to expand its operational footprint, Zynerba Pharmaceuticals remains dedicated to improving patient outcomes through innovative solutions.
DitchCarbon Score
How does Zynerba Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zynerba Pharmaceuticals, Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zynerba Pharmaceuticals, Inc.'s reported carbon emissions
Zynerba Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting ambitious targets to reduce their carbon footprint. However, without specific initiatives or commitments disclosed by Zynerba Pharmaceuticals, it is unclear what steps they are taking towards climate responsibility. As the industry evolves, it is anticipated that Zynerba may adopt more robust climate strategies and reporting in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zynerba Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
